Efficacy of R-CHOP14 treatment regimen for elderly patients with non-Hodgkins lymphoma

ObjectiveTo explore adverse reactions and clinical efficacy of treatment regimen of rituximab monoclonal antibody combined with CHOP regimen(R-CHOP14)for elderly patients with non-Hodgkin's lymphoma(NHL) and to examine the influence of R-CHOP14 on immune function.MethodsWith a retrospective study,70 elderly patients with NHL were divided into R-CHOP14 regimen group(24),CHOP14 group(23),and CHOP21 group(23).After 6 courses of treatment,the efficacy and the occurrence of adverse reactions were observed.ResultsThe rate of complete remission(CR)of the R-CHOP14 group was 70.8%,with an overall effective rate of 83.3%.The CR rate of the CHOP14 group was 39.2% with an overall effective rate of 65.2%.The CR rate of the CHOP21 group was 34.8%,with an overall effective rate of 56.6%.The CR rate of R-CHOP14 group was significantly higher than that of CHOP14 group and CHOP21 group.But adverse reactions showed no significant difference among the 3 groups(P> 0.05).ConclusionR-CHOP14 treatment regimen for elderly patients with NHL has good efficacy and less side effects,high titer,good tolerance,but it could lead to impaired immune function and increase in infection incidence.